Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8755186 | 1.00 | HPGD (0.59) | HPGDMMEMMEL1LMNAPOLB | |
| SCHEMBL13273976 | 0.87 | HPGD (0.45) | HPGDMMEMMEL1 | |
| SCHEMBL8778403 | 0.85 | PRSS1 (0.47) | HPGDLMNAPOLB | |
| SCHEMBL12294985 | 0.81 | HPGD (0.70) | HPGDMMELMNAPOLB | |
| SCHEMBL7301124 | 0.81 | BACE1 (0.52) | MMEMMEL1 | |
| SCHEMBL2543478 | 0.80 | HPGD (0.60) | HPGDMMELMNAPOLB | |
| SCHEMBL9272431 | 0.80 | HPGD (0.60) | HPGDMMELMNAPOLB | |
| SCHEMBL23921461 | 0.80 | ACE (0.58) | MMELMNA | |
| SCHEMBL21777483 | 0.80 | ACE (0.58) | MMELMNA | |
| SCHEMBL12009636 | 0.80 | HPGD (0.68) | HPGDMMELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110229581-A1 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229581-A1 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | APLNR, LPAR6, ABHD16A | HPGD 4508/4885MME 2237/4885MMEL1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.